PLX

Protalix BioTherapeutics, Inc. (PLX) SWOT Analysis Analysis (2026)

Invetso Score: 5.6/10 — Balanced · Last Updated: 2026-08-01

Strengths

ROIC of 23.3% indicates PLX converts capital into returns well above typical peers, supporting durable value creation and pricing discipline.

Net debt to EBITDA of -0.7x implies net cash, giving PLX more balance-sheet flexibility than leveraged peers and reducing refinancing pressure.

Current ratio of 2.94x and quick ratio of 1.91x show liquidity materially stronger than most peers, supporting operational resilience through demand volatility.

Low debt-to-equity of 0.13x suggests conservative leverage versus peers, which can preserve strategic optionality and limit earnings sensitivity to rates.

Weaknesses

Cash conversion cycle of 453.7 days is structurally long versus peers, tying up working capital and limiting the speed of cash reinvestment.

The absence of disclosed margin metrics weakens visibility on operating efficiency versus peers, making it harder to evidence a durable cost advantage.

The absence of multi-year growth metrics limits proof that PLX is outgrowing peers, constraining confidence in sustained share gains.

Liquidity is strong, but the very long cash cycle suggests working-capital intensity remains a structural drag relative to more efficient peers.

Opportunities

If PLX shortens its 453.7-day cash conversion cycle, it could release meaningful cash versus peers and improve reinvestment capacity.

Strong liquidity and net cash provide room to fund working-capital optimization ahead of peers without stressing the balance sheet.

High ROIC creates a favorable base for incremental capital deployment, so any growth initiative can compound value faster than lower-return peers.

Limited segment and growth disclosure suggests upside may exist from portfolio simplification or mix improvement, but peer-relative evidence is currently incomplete.

Threats

Peers with faster cash cycles can compound capital more efficiently, leaving PLX at a structural disadvantage if working-capital intensity persists.

If demand weakens, PLX's long cash cycle could amplify cash absorption versus peers, even though leverage is currently low.

The lack of margin disclosure raises the risk that peers may be structurally more efficient on cost, pressuring relative competitiveness.

Without visible growth segmentation, PLX may face harder peer comparison on market-share momentum, which can weigh on valuation durability.

Overall Score

PLX appears financially resilient and high-returning versus peers, but its very long cash conversion cycle and limited operating disclosure temper overall structural positioning.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Protalix BioTherapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →